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Background: To identify relevant factors predicting the need for insulin therapy 
in women with gestational diabetes mellitus (GDM) and secondly to determine 
a potential “low-risk” diet-treated group who are likely to have good pregnancy 
outcomes.
Methods: A retrospective analysis between 2011-2014. Multivariable backward 
stepwise logistic regression was used to identify the predictors of the need for 
insulin therapy. To identify a “low-risk” diet-treated group, the group was stratified 
according to pregnancy complications. Diet-treated women with indications for 
induction in secondary care were excluded. 
Results: A total of 820 GDM women were included, 360 (44%) women required 
additional insulin therapy. The factors predicting the need for insulin therapy 
were: previous GDM, family history of diabetes, a previous infant weighing ≥4500 
gram, Middle-East/North-African descent, multiparity, pre-gestational BMI ≥30 kg/
m2, and an increased fasting glucose level ≥5.5 mmol/l (OR 6.03;CI 3.56-10.22) and 
two-hour glucose level ≥9.4 mmol/l after a 75-gram oral glucose tolerance test at 
GDM diagnosis. In total 125 (54%) women treated with diet-only had pregnancy 
complications. Primiparity and higher weight gain during pregnancy were the best 
predictors for complications (predictive probability 0.586 and 0.603).
Conclusion: In this GDM population we found various relevant factors predicting 
the need for insulin therapy. A fasting glucose level ≥5.5 mmol/l at GDM diagnosis 
was by far the strongest predictor. Women with GDM who had good glycaemic 
control on diet-only with a higher parity and less weight gain had a lower risk for 
pregnancy complications. 




Gestational diabetes mellitus (GDM) is one of the most common metabolic complica-
tions during pregnancy and occurs in 1-14% of all pregnancies, depending on the 
population demographics and the diagnostic criteria used.1 Given that obesity is a 
worldwide epidemic and the recent more stringent guidelines for screening and diag-
nosis, the prevalence of GDM is still increasing which burdens obstetric care systems.2-7 
GDM is associated with an elevated risk of adverse obstetric and neonatal out-
comes during pregnancy.8-11 However, studies demonstrated that GDM is a treatable 
condition and controlling blood glucose levels throughout pregnancy can reduce 
the risk of complications.12-13 Dietary advice is the first step and cornerstone in GDM 
treatment. When diet fails, insulin therapy is the second step in treatment, accord-
ing to almost all international guidelines.14
In our country, we have a special obstetric care system which is divided between 
primary and secondary care. The primary care is organised by independently prac-
tising midwives and general practitioners (GP’s) who take care of normal pregnancy 
and childbirth, and secondary care is organised by in-hospital obstetricians and 
specialised clinical midwives caring for pathological pregnancy and childbirth or 
pregnancies accompanied by comorbidity.15 
Since GDM pregnancies are at increased risk for adverse obstetric and neonatal 
outcomes, women with GDM are referred to hospitals for obstetric care and are 
advised to give birth in a hospital with good neonatal facilities. This is especially ap-
plicable for women with GDM who are treated with additional insulin therapy and 
who are considered to present a more severe GDM group due to a greater difficulty 
to maintain glycaemic control.16 
However, there may be “low-risk” women with GDM who do not need obstetric 
care in secondary care but can maintain care from their midwives or GP’s. Women 
with GDM treated with diet only might be the potential “low-risk” group who could 
be treated in a low-risk setting and even qualify for delivery at home. Such a policy 
demands the correct identification of women with GDM with a high-risk of adverse 
pregnancy outcomes. 
In an earlier paper, we reported the neonatal and obstetric outcomes of preg-
nancies complicated with GDM after implementation of the 2010 Dutch Society of 
Obstetrics and Gynaecology GDM guideline on screening and treatment – diet only 
versus additional insulin therapy – and we compared these outcomes with the gen-
eral obstetric population in the northern region of the Netherlands.17 In the present 
study we aim to identify relevant factors predicting the need for insulin therapy 
in women with GDM and secondly to determine a potential “low-risk” diet-treated 




Study population and design
The study population consisted of all women with singleton pregnancies who were 
diagnosed with GDM according to the Dutch national guidelines in the University 
Medical Center Groningen and in the Martini Hospital Groningen, between January 
2011 and September 2014. As previously reported,17 pregnant women were recom-
mended to undergo a 75-gram oral glucose tolerance test (OGTT) at week 24-28 
of gestation if they had one or more risk factors for GDM according to the Dutch 
national guideline: previous GDM, first degree relative with type 2 diabetes mellitus 
(DM), a previous neonate weighing ≥4500 gram, pre-pregnancy body mass index 
(BMI) ≥30 kg/m2, some ethnic risk groups (South-Asian, Hindu, African-Caribbean, 
Middle Eastern, Morocco and Egypt), history of intrauterine foetal death (IUFD), and 
history of polycystic ovary syndrome (PCOS). Also women with signs suggestive 
of GDM (e.g. polyhydramnios and/or foetal macrosomia) were screened.14 Women 
with previous GDM were screened at week 16-18 of gestation and when the test 
was negative, it was repeated at week 24-28 of gestation. GDM was diagnosed if 
the fasting plasma glucose was ≥7.0 mmol/l and/or the two-hour plasma glucose 
≥7.8 mmol/l. In addition, GDM was diagnosed if fasting glucose was >7.0 mmol/l or 
random glucose was >11.1 mmol/l.14,18 The guideline uses these diagnostic criteria, 
based on the criteria of the World Health Organization (WHO) 1999.18 
Women with a twin pregnancy (n=15) and women with missing data on neonatal 
complications (n=4) were excluded. Women with pre-existing diabetes were not 
included in the study. This study has been exempted for approval according to the 
Medical Research Involving Human Subjects Act. This report is based on patient data 
acquired during care as usual, the data were analysed retrospectively and all the 
requirements for patient anonymity are in agreement with the regulations of the 
ethics committee of both hospitals. According to this and the Dutch law on Medical 
Research with Human Subjects, no approval from an ethics committee is necessary.
GDM treatment regimens
All women diagnosed with GDM received dietary advice by a trained dietician, which 
included education about carbohydrate intake and carbohydrate distribution. The 
women also received instructions regarding self-monitoring of blood glucose levels 
by a diabetes specialist nurse and were instructed to measure fasting and one-hour 
postprandial blood glucose levels every day for one week. After 1-2 weeks the 
blood glucoses values were evaluated at the diabetes outpatient clinic. If the fast-
ing plasma glucose level was >5.3 mmol/l and/or postprandial plasma glucose level 
>7.8 mmol/l additional insulin therapy was started. Insulin was commenced with 
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two elevated blood glucose levels on two successive days and no expected ben-
efits of further dietary intervention. There were three options for insulin therapy: 
once daily long-acting, prandial ultrashort-acting insulin or a combination of both 
(basal-bolus regimen), depending on the specific glycaemic profile. In both centres 
short-acting insulin analogues and NPH insulin were used in GDM treatment.
Measures
All data were assessed from medical and birth records. Ethnicity was classified 
into four categories: Caucasian, African-American, Middle-Eastern/North-African 
descents, and Asian (Indian or South-East Asian). Family history of diabetes was 
defined as having a first-degree relative with type 2 DM. Weight gain was calculated 
from pre-pregnancy weight to the first visit. HbA1c values were measured by stan-
dardised HPLC method on a Tosoh G8 system (Tosoh, Tokyo, Japan), considering 
22-42 mmol/mol (4.2-6.0%) as normal. The HbA1c values were measured at the time 
of GDM diagnosis within one week after the OGTT.
Neonatal complications included: a composite outcome of perinatal compli-
cations (still-birth/neonatal death, birth trauma (shoulder dystocia, fracture of 
humerus or clavicle), hyperbilirubinaemia and neonatal hypoglycaemia), large for 
gestational age (defined as birth weight above the 90th percentile, adjusted for age, 
gender, parity, and ethnicity),19 small for gestational age (defined as birth weight 
below the 10th percentile, adjusted for age, gender, parity, and ethnicity),19 preterm 
delivery (defined as delivery <37 weeks), Apgar score <7 at 5 minutes, and admis-
sion to the neonatology department. The presence of neonatal hypoglycaemia was 
defined as a blood glucose level <2.6 mmol/l or treatment with a glucose infusion. 
Obstetric complications included: instrumental delivery (forceps or vacuum extrac-
tion), planned caesarean section and secondary caesarean section. 
Statistical analyses
Maternal characteristics are presented according to the GDM treatment regimens. 
Continuous data are presented as mean with standard deviation or as median and 
inter quartile range [IQR] in case of skewed distribution. Categorical data are pre-
sented as number and percentage. For continuous data, the differences between 
the groups were tested using Student’s unpaired t-test or the Mann-Whitney U test 
in case of skewed distribution. Categorical variables were compared using Chi-
square test and Fisher’s exact test. 
To examine the potential predictors of need for insulin therapy in GDM, analyses 
were performed using logistic regression models to calculate the odds ratios (ORs) and 
95% confidence intervals (95% CIs). Factors considered in the model were: maternal 
age, smoking during pregnancy, parity, ethnicity, history of PCOS, history of IUFD, pre-
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gestational BMI, previous GDM, previous neonate weighing ≥4500 gram, first-degree 
relative with diabetes, chronic hypertension, HbA1c, fasting glucose level at time 
of GDM diagnosis (quartiles), and two-hour glucose level after a 75-gram OGTT at 
time of GDM diagnosis (quartiles). First univariable logistic regression was performed 
and significant factors (two-sided P-value <0.10) were included in a multivariable 
backward stepwise logistic regression model to determine the final model. In the final 
prediction model a two-sided P-value <0.10 was considered statistical significant. 
To determine a potential “low-risk” diet-treated group, women with other indica-
tions for induction in secondary-care – according to the “List of Obstetric Indications” 
used by midwives in the Netherlands20 – were excluded. The diet group was stratified 
in a group without and with obstetric and/or neonatal complications as defined 
above. Comparison between the risk groups was applied using Mann-Whitney U 
test or Chi-square test. Receiver operating characteristics curves analysis was used 
to evaluate the predicted probability. All P-values were two-sided and P <0.05 was 
TABLE 1. Comparison of the characteristics between GDM women treated with diet only and the women 








Age (years) 32.0 ± 5.1 31.6 ± 4.9 32.6 ± 5.2 0.010
Family history of diabetes, n (%) 326 (39.8) 156 (33.9) 170 (47.2) <0.001
Previous gestational diabetes mellitus, n (%) 86 (10.5) 25 (5.4) 61 (16.9) <0.001
Previous infant weighing ≥4500 g, n (%) 90 (11.0) 35 (7.6) 55 (15.3) <0.001






















Weight gain mother (kg)† 8.0 [4.0-12.0] 9.0 [5.0-13.0] 7.0 [3.0-11.0] <0.001
Fasting glucose level (mmol/l) 5.0 [4.6-5.5] 4.8 [4.5-5.2] 5.3 [4.9 5.9] <0.001











Abbreviations: IUFD, intrauterine foetal death; BMI, body mass index.
Data are expressed as mean ± SD, median [IQR], or proportion n (%).
Data with respect to family history of diabetes, pre-gestational body mass index, weight gain mother, and 
HbA1c are missing in 24 (2.9%), 25 (3.0%), 225 (27.4%), 177 (21.6%) of the women, respectively. 
* P-values were based on Student’s unpaired t-test (non-skewed continuous variables), Mann-Whitney U Test 
(skewed continuous variables) or Chi-square test (categorical variables).
† Weight gain from pre-pregnancy weight to first visit.
‡ The HbA1c values were measured at the time of GDM diagnosis within 1 week after.
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considered statistical significant. All statistical analyses were performed with the use 
of the statistical package IBM SPSS Statistics (version 22.0. Armonk, NY: IBM Corp). 
RESULTS
Maternal characteristics
The most important characteristics of the study population are summarized in Table 
1. A total of 820 GDM women were referred for treatment, 460 women (56%) were 
able to maintain adequate glycaemic control with dietary advice only, while 360 (44%) 
required additional insulin therapy. Of the women who required insulin therapy, 143 
women (40%) received trice daily pre-prandial ultrashort-acting insulin, 165 women 
TABLE 2. Multivariable logistic regression analyses of predictors for additional insulin therapy.
Predictors OR 95% CI P-value*
Previous gestational diabetes 2.05 1.13-3.70 0.018
Family history of diabetes 1.90 1.36-2.66 <0.001




































































Abbreviations: OGTT, oral glucose tolerance test; OR, odds ratio.
ORs, 95% confidence intervals and P-values were derived from logistic regression models (backward- stepwise 
method).
* P-value <0.10 was considered statistical significant.
** The fasting glucose level and two-hour glucose at time of GDM diagnosis.
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(46%) received basal-bolus insulin therapy, and 39 women (11%) received once long-
acting insulin (for 13 women type of insulin was not recorded) at the end of their 
pregnancy. The median insulin dose was 22 U/day; IQR 12-42 U/day. 
The women in the insulin group were older, were more often multiparous, 
and had a higher pre-gestational BMI. No differences in earlier diagnosis of PCOS, 
hypertension, history of spontaneous abortion, smoking during pregnancy, and 
ethnicity were observed between the groups. The frequency rates of previous GDM, 
a previous neonate weighing ≥4500 gram at birth, and first degree relative with 
diabetes were higher in the insulin group. The median fasting glucose level and 
two-hour glucose level after a 75-gram OGTT at time of GDM diagnosis were higher 
in the insulin group compared with the diet group. 
Predictors of need for insulin therapy
Table 2 shows the significant predictors of need for insulin therapy. Previous GDM, 
family history of diabetes, a previous infant weighing ≥4500 gram, Middle-Eastern/
North-African descent, multiparity, pre-gestational BMI ≥30 kg/m2, and an increased 
fasting glucose level and two-hour glucose after a 75-gram OGTT at GDM diagnosis 
were significant predictors of need for insulin therapy, with a fasting glucose level 
≥5.5 mmol/l having the highest OR 6.03; CI 3.56-10.22.





























Abbreviations: IUFD, intrauterine foetal death.
* Indications are based on the List of Obstetric Indications used by midwives in the Netherlands. 
** Some women had more than one indication for treatment in secondary care.
† Chronic hypertension was defined as a pre-gestational systolic blood pressure (SBP) ≥140 mmHg and/or a dia-
stolic blood pressure (DBP) ≥90 mmHg on two occasions or the use of blood-pressure lowering drugs.
‡ Pre-eclampsia was defined as a combination of gestational hypertension and proteinuria (≥300 mg/24-h) and 
included eclampsia and haemolysis elevated liver enzymes and low platelets (HELLP) syndrome.
¶ Post-term pregnancy was defined as being pregnant for 42 weeks.
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Stratification diet-treated group 
Of the 460 diet-treated women, 229 women (49.8%) were excluded because of other 
indications for induction. Table 3 gives an overview of these indications. Table 
4 shows GDM pregnancies without (106 women (45.9%)) and with (125 women 
(54.1%)) obstetric and/or neonatal complications. Primiparity and higher weight 
gain during pregnancy were the best predictors for complications (predictive prob-
ability 0.586 and 0.603) respectively.
TABLE 4. Identification of a low-risk group of diet-treated women with gestational diabetes according to 







































Pre-gestational BMI (kg/m2) 28.0 [23.0-31.9] 27.6 [22.7-31.1] 28.5 [23.5-32.6] 0.290
Weight gain mother (kg)† 8.0 [4.0-11.0] 7.0 [3.0-10.0] 9.0 [4.9-12.3] 0.019
Fasting glucose level (mmol/l) 4.8 [4.5-5.2] 4.8 [4.5-5.2] 4.7 [4.5-5.2] 0.670











Abbreviations: BMI, body mass index; OGTT, Oral Glucose Tolerance Test. 
Data are expressed as mean ± SD, median [IQR] or proportion n (%).
Data with respect to total risks factors for gestational diabetes (GDM), pre-gestational BMI, weight gain mother, 
and HbA1c are missing in 13 (5.6%), 9 (3,9%), 56 (24.2%), 55 (23.8%) of the women, respectively.
*P-values were based on Student’s unpaired t-test (non-skewed continuous variables), Mann-Whitney U Test 
(skewed continuous variables) or Chi-square test (categorical variables).
**Complications during pregnancy, including: perinatal complications (perinatal mortality, birth trauma, hyper-
bilirubinaemia and neonatal hypoglycaemia), large for gestational age (birth weight above the 90th percentile), 
small for gestational age (birth weight below the 10th percentile), Apgar score <7 after 5 minutes, preterm deliv-
ery <37 weeks, admission to neonatology, instrumental delivery, and (elective) caesarean section.
§Risk factors for GDM were: a previous GDM, first degree relative with type 2 diabetes mellitus, a previous neonate 
weighing ≥4500 gram, pre-pregnancy BMI ≥30 kg/m2, some ethnic risk groups (South-Asian, Hindu, African-
Caribbean, Middle Eastern, Morocco and Egypt), history of intrauterine foetal death, and history of polycystic 
ovary syndrome.




In this study we identified the following risk factors in GDM that predicted the need 
for additional insulin therapy: previous GDM, family history of diabetes, a previous 
infant weighing ≥4500 gram, Middle-Eastern/North-African descent, multiparity, 
pre-gestational BMI ≥30 kg/m2, and a markedly increased fasting and two-hour 
glucose level after a 75-gram OGTT at time of GDM diagnosis. A fasting glucose 
level ≥5.5 mmol/l at time of GDM diagnosis was the strongest predictor of need for 
insulin therapy. 
Moreover, the study showed that diet-treated primiparous women with GDM 
had more obstetric and/or neonatal complications compared with multiparous. 
Also, a higher weight gain in diet-treated women with GDM was associated with 
more pregnancy complications. 
Predictors of need for insulin therapy
Women who receive dietary advice but fail to maintain glycaemic control within 1-2 
weeks generally receive additional insulin therapy. In several studies insulin therapy 
was required in ~20-30% of the women with GDM.12,13,21,22 In our study a higher 
percentage (44%) of women with GDM required additional insulin therapy. This is in 
line with two other studies which reported that 51-53% needed insulin therapy.23,24 
Possible explanations for the wide range in percentages for insulin need between 
studies are: differences in the study population, dietary compliance, criteria for 
diagnosis of GDM, and criteria to start insulin therapy. 
A number of previous studies have addressed the possible predictors of the 
need for insulin therapy in women with GDM. In analogy to our study, three compa-
rable studies with regard to sample size and ethnicity showed that elevated fasting 
plasma glucose at time of GDM diagnosis was a potent predictor for additional insu-
lin therapy.23-25 One study25 showed in a large cohort of 2365 women with GDM that 
women requiring insulin therapy were more likely to have a fasting blood glucose of 
>5.3 mmol/l (>95 mg/dl) before a 100-gram OGTT. Moreover, the study found that 
multiparity, obesity, history of GDM, diagnosis, a three-hour glucose tolerance test 
>7.8 mmol/l (>140 mg/dl), and HbA1c of ≥6.0% at GDM diagnosis were additional 
predictors of need for insulin therapy. In a second study,23 BMI, gestational age when 
GDM was diagnosed, and fasting and two-hour glucose levels after a 75-gram OGTT 
were independent predictors of insulin therapy among 612 women with GDM. For 
each increase of 0.5 mmol/l to the level of the fasting glucose, they reported an OR 
for insulin therapy of 2.75. The last study24 identified a number of significant predic-
tors for insulin including measures of glycaemia – fasting glucose level – diagnosis, 
Risk stratification in women with GDM
77
4
and family history of GDM among 3009 women with GDM. However, they found a 
low predictive power for the risk factors. 
Although the aforementioned studies used different glucose targets and screen-
ing strategies, comparable results regarding fasting glucose levels were observed. 
Similar to our study, these studies used “old” diagnostic criteria, before the imple-
mentation of the more stringent criteria of the International Association of Diabetes 
and Pregnancy Study Groups (IADPSG) in 2010.23,24 The fasting glucose level – at 
time of GDM diagnosis – found in our study (≥5.5 mmol/l) is comparable with the 
national recommended fasting glucose target for start of insulin treatment (≥5.3 
mmol/l), but much lower than the fasting glucose level used to diagnose GDM (≥7.0 
mmol/l) according to our current national guideline. The fasting glucose level is 
more comparable with the new diagnostic criteria adopted by the IADPSG and the 
WHO 2013 (fasting glucose ≥5.1 mmol/l; one-hour ≥10.0 mmol/l; and a two-hour 
value ≥8.5 mmol/l).26,27 Revision of the diagnostic criteria of our national guideline 
seems justified, to overcome the discrepancy between the diagnostic cut-off and 
treatment target values of fasting glucose in GDM. 
The fasting glucose level was a more potent predictor of the need for insulin 
therapy than the two-hour glucose level at time of the OGTT. The finding that a 
fasting glucose level is a strong predictor for insulin therapy may be explained by 
the pathophysiology of GDM and type 2 DM. In GDM, fasting glucose levels may 
remain normal, when insulin resistance is initially compensated by increased insulin 
production and therefore the abnormality might only be seen in the postprandial 
blood glucose values.28 However, it has been demonstrated that GDM women not 
only have defects in insulin sensitivity but also in insulin secretion.28 Studies also 
suggest that the fasting glucose level on diagnostic OGTT is more associated with a 
defect in basal insulin secretion; this might be a plausible explanation why the fast-
ing glucose level is a strong predictor for the need of insulin.29,30 Finally, it has been 
shown that elevated glucose levels during pregnancy also predict the development 
of type 2 DM after pregnancy.31 So it may be that women with more pronounced 
increased fasting plasma glucose are already in an advanced stage to develop type 
2 DM. 
Stratification diet-treated group
After the findings on the benefits of GDM treatment, worldwide revisions of the 
guidelines for screening and diagnosis of GDM were performed.9,12,13 Lowering the 
diagnostic threshold strongly increases the number of women referred for treat-




This study allowed the recognition of a more complex-care group of insulin-
treated women with GDM, but on the other hand a potential “low-risk” group of 
women who can be treated with diet alone, and who could possibly be referred 
back to primary care. Only primiparity and weight gain during pregnancy were risk 
factors to develop obstetric and/or neonatal complications in the diet group, but 
these risk factors had a very low predictive probability. The rather large proportion 
of 54% of the diet-treated women who suffered pregnancy-related complications 
could not validly be identified beforehand. Therefore, it is not possible to identify 
a circumscribed “low-risk” diet-treated group from our data based on pregnancy 
outcomes. As some authors suggest that diet-treated women – who are likely to 
maintain good glycaemic control throughout pregnancy with diet-only – can be 
referred back to midwives in primary care,23,32 there remains uncertainty regarding 
the possible development of pregnancy-related complications. To be able to refer 
women back to primary care, a healthcare system with optimal interaction and 
communication between primary and secondary care is required. However, such 
shared-care models require further evaluation for GDM care. There is more need for 
prospective studies investigating the safety of treating diet-only women with GDM 
in primary care. 
The strengths of the study are the large cohort of women with GDM and the 
large database with the collection of commonly used measures. A limitation of the 
study is the retrospective nature of the analyses and the fact that this GDM cohort is 
based on the “old” WHO 1999 diagnostic criteria for GDM in our national guideline, 
which differ greatly from the new WHO 2013 criteria, while for treatment of GDM we 
use the new stringent international glucose targets in GDM pregnancies. This dis-
crepancy clearly needs reconsideration of the current Dutch guideline on diagnosis 
and treatment of GDM.
In summary, in this GDM population we found various relevant factors predict-
ing the need for additional insulin therapy in GDM. Especially, a fasting glucose 
level ≥5.5 mmol/l at GDM diagnosis was the strongest predictor of need for insulin 
therapy. These predictors might be helpful to recognise a complex-care group of 
insulin-treated women within the GDM population. Women with GDM who had 
good glycaemic control on diet only with a higher parity and less weight gain, had 
a lower risk for obstetric and/or neonatal complications. However, from our data 
a risk-stratification approach for the diet group based on neonatal and obstetric 
complications alone did not have predictive utility. 
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